Atezolizumab At Last: Roche Makes Its Immuno-Oncology Debut

FDA's accelerated approval of Tecentriq, the first PD-L1 inhibitor, in bladder cancer is a major milestone for checkpoint inhibitors and for a disease with high unmet need; lung filing still under review.